



Drug Coverage Policy

Effective Date1/15/2025

Coverage Policy Number.....IP0600

Policy Title..... Adempas

Pulmonary Arterial Hypertension–Adempas

- Adempas® (riociguat tablets - Bayer)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Cigna Healthcare Coverage Policy

OVERVIEW

Adempas, a soluble guanylate cyclase stimulator, is indicated for the treatment of adults with:¹

- **Chronic thromboembolic pulmonary hypertension (CTEPH)** [World Health Organization {WHO} Group 4], persistent/recurrent, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
- **Pulmonary Arterial Hypertension (PAH) WHO Group 1**, to improve exercise capacity, WHO functional class, and to delay clinical worsening.

Disease Overview

PAH is a serious but rare condition impacting fewer than 20,000 patients in the US.^{2,3} It is classified within Group 1 pulmonary hypertension among the five different groups that are recognized. In this progressive disorder, the small arteries in the lungs become narrowed, restricted, or blocked causing the heart to work harder to pump blood, leading to activity impairment.^{2,3} Although the mean age of diagnosis is between 36 and 50 years, patients of any age may be affected, including pediatric patients. PAH is defined as a mean pulmonary artery pressure (mPAP) > 20 mmHg (at rest) with a pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg and a pulmonary vascular resistance > 2 Wood units measured by cardiac catheterization.⁷ The prognosis in PAH has been described as poor, with the median survival being approximately 3 years. However, primarily due to advances in pharmacological therapies, the long-term prognosis has improved.

CTEPH is a persistent obstruction of pulmonary arteries and is often a complication of pulmonary embolism.^{4,5} It is classified within WHO Group 4 pulmonary hypertension. Symptoms include progressive dyspnea on exertion, as well as fatigue, syncope, hemoptysis, and signs of right heart failure. Pulmonary endarterectomy is the treatment of choice for most patients with CTEPH. However, around 40% of patients are deemed inoperable for various reasons. Medication therapy, including Adempas, may also be recommended. Anticoagulant therapy is also given.

Guidelines

Various guidelines are available for the management of pulmonary hypertension.

- **Pulmonary Arterial Hypertension:** The CHEST guideline and Expert Panel Report regarding therapy for PAH in adults (2019) cites Adempas as a vital therapy with several benefits in a variety of clinical scenarios. The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) guidelines regarding the treatment of pulmonary hypertension (2022) also recognize Adempas as having a prominent role in the management of this condition, as monotherapy or in combination with other agents.
- **Chronic Thromboembolic Pulmonary Hypertension:** Guidelines from the ESC/ERS regarding the treatment of pulmonary hypertension (2022) recommended Adempas for patients who are symptomatic with inoperable CTEPH or persistent/recurrent pulmonary hypertension after pulmonary endarterectomy.⁶

Medical Necessity Criteria

Adempas is considered medically necessary when ONE of the following is met (1 or 2):

FDA-Approved Indications

1. **Chronic Thromboembolic Pulmonary Hypertension.** Approve for 1 year if prescribed by or in consultation with a pulmonologist or a cardiologist.
2. **Pulmonary Arterial Hypertension (PAH) [World Health Organization {WHO} Group 1].** Approve for the duration noted if the patient meets ONE of the following (A or B):
 - A) **Initial Therapy.** Approve for 1 year if the patient meets all of the following (i, ii, and iii):
 - i. Patient has a diagnosis of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH); AND
 - ii. Patient meets the following (a and b):
 - a) Patient has had a right heart catheterization; AND
 - b) Results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH; AND
 - iii. Medication is prescribed by or in consultation with a cardiologist or a pulmonologist.

- B) Patient is Currently Receiving Adempas.** Approve for 1 year if the patient meets all of the following (i, ii, and iii):
- i.** Patient has a diagnosis of WHO Group 1 PAH; AND
 - ii.** Patient meets the following (a and b):
 - a)** Patient has had a right heart catheterization; AND
Note: This refers to prior to starting therapy with a medication for WHO Group 1 PAH.
 - b)** Results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH; AND
 - iii.** Medication is prescribed by or in consultation with a cardiologist or a pulmonologist.

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Receipt of sample product does not satisfy any criteria requirements for coverage.

Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

- 1. Concurrent Use with Phosphodiesterase Inhibitors Used for Pulmonary Hypertension or Other Soluble Guanylate Cyclase Stimulators.** Use of Adempas with phosphodiesterase inhibitors and/or with other soluble guanylate cyclase stimulators is a contraindication.¹
Note: Examples of phosphodiesterase inhibitors used for pulmonary hypertension include Revatio (sildenafil tablets, suspension, and intravenous injection), Adcirca (tadalafil tablets), Alyq (tadalafil tablets), and Tadiq (tadalafil oral suspension). An example of a soluble guanylate cyclase stimulator is Verquvo (vericiguat tablets).

References

1. Adempas® tablets [prescribing information]. Whippany, NJ: Bayer; January 2023.
2. Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension. A review. *JAMA*. 2022;327(14):1379-1391.
3. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults. Update of the CHEST guideline and Expert Panel Report. *CHEST*. 2019;155(3):565-586.
4. Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2019;53(1):1801915.
5. Papamatheakis DG, Poch DS, Fernandes TM, et al. Chronic thromboembolic pulmonary hypertension: JACC focus seminar. *J Am Coll Cardiol*. 2020;76(18):2155-2169.
6. Humbert M, Kovacs G, Hoeper MM, et al, for the ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2022;43(38):3618-3731.
7. Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. *J Am Heart Assoc*. 2023 Apr 18;12(8): e029024. [Epub].

Revision Details

Type of Revision	Summary of Changes	Date
New	New policy	6/1/2024

	<ul style="list-style-type: none"> • New stand-alone policy created; criteria previously housed in Pulmonary Hypertension Therapy class policy. • Removed age 18 and older requirement from previous criteria. • For CTEPH: removed “persistent/recurrent” and “after surgical treatment or if inoperable” • Updated confirmation of PAH diagnosis, to remove echocardiogram as an option. • Relocated and updated concurrent use statement to the “Conditions Not Covered section” and now also includes Other Soluble Guanylate Cyclase Stimulators. 	
Annual Revision	Pulmonary Arterial Hypertension (PAH) [World Health Organization {WHO} Group 1]: For a patient currently receiving Adempas, added a <i>note</i> to indicate that requirement of a right heart catheterization (RHC) refers to a RHC prior to starting therapy with a medication for WHO Group 1 PAH.	1/15/2025

The policy effective date is in force until updated or retired.

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.